Merrill J E, Scolding N J
CNS Division, Hoechst Marion Rousse, Bridgewater, NJ, USA.
Neuropathol Appl Neurobiol. 1999 Dec;25(6):435-58. doi: 10.1046/j.1365-2990.1999.00200.x.
Oligodendrocytes synthesize and maintain myelin in the central nervous system (CNS). Damage may occur to these cells in a number of conditions, including infections, exposure to toxins, injury, degeneration, or autoimmune disease, arising both in the course of human disease and in experimental animal models of demyelination and dysmyelination; multiple sclerosis is the commonest human demyelinating disorder. Conventional classical accounts of the pathology of this and other myelin diseases have given great insights into their core features, but there remain considerable uncertainties concerning the timing, means and cause(s) of oligodendrocyte and myelin damage. At present, therapeutic efforts largely concentrate on immune manipulation and damage limitation, an approach that has produced only modest effects in multiple sclerosis. One reason for this must be the limited understanding of the mechanisms underlying cell damage - clearly, successful therapeutic strategies for preserving the oligodendrocyte-myelin unit must depend on knowledge of how oligodendrocyte damage and death occurs. In this review, mechanisms of oligodendrocyte and myelin damage are considered, and attempts made to relate them to disease processes, clinical and experimental. The hallmarks of different cell death processes are described, and oligodendrocyte-myelin injury by cellular and soluble mediators is discussed, both in vitro and invivo. Recent developments concerning the pathological involvement of oligodendrocytes in neurodegenerative disease are summarized. Finally, these neuropathological and applied neurobiological observations are drawn together in the context of multiple sclerosis.
少突胶质细胞在中枢神经系统(CNS)中合成并维持髓鞘。在多种情况下,包括感染、接触毒素、损伤、变性或自身免疫性疾病,这些细胞可能会受损,这些情况既会在人类疾病过程中出现,也会在脱髓鞘和髓鞘形成异常的实验动物模型中出现;多发性硬化症是人类最常见的脱髓鞘疾病。关于这种疾病和其他髓鞘疾病的病理学的传统经典描述对其核心特征有了深入了解,但关于少突胶质细胞和髓鞘损伤的时间、方式和原因仍存在相当大的不确定性。目前,治疗努力主要集中在免疫调节和损伤限制上,这种方法在多发性硬化症中只产生了适度的效果。其中一个原因肯定是对细胞损伤潜在机制的了解有限——显然,保护少突胶质细胞 - 髓鞘单元的成功治疗策略必须依赖于对少突胶质细胞损伤和死亡发生方式的了解。在这篇综述中,我们考虑了少突胶质细胞和髓鞘损伤的机制,并试图将它们与疾病过程、临床和实验联系起来。描述了不同细胞死亡过程的特征,并讨论了细胞和可溶性介质在体外和体内对少突胶质细胞 - 髓鞘的损伤。总结了少突胶质细胞在神经退行性疾病中的病理参与的最新进展。最后,在多发性硬化症的背景下,将这些神经病理学和应用神经生物学观察结果汇总在一起。